For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 26,879,146 | |||
| General and administrative | 32,221,054 | |||
| Total operating expenses | 59,100,200 | |||
| Loss from operations | -59,100,200 | |||
| Interest/investment income, net | 1,395,989 | |||
| Realized (loss) gain on short-term investments | -79,207 | |||
| Unrealized gain on short-term investments | 398,255 | |||
| Total other income (expenses), net | 1,715,037 | |||
| Net loss | -57,385,163 | |||
| Basic EPS | -1.45 | |||
| Diluted EPS | -1.45 | |||
| Basic Average Shares | 39,479,694 | |||
| Diluted Average Shares | 39,479,694 | |||
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)